Vestec, Czech Republic – EXBIO the leading manufacturer of monoclonal antibodies and reagents for research and clinical applications with the focus on multi-color flow cytometry analysis of human cellular markers, is pleased to announce its acquisition of Apronex.
Apronex are experts in recombinant protein technologies.
The acquisition of Apronex further expands EXBIO product offering and strengthens the company’s position as one of the fastest growing providers in the clinical flow cytometry reagent market. Through its partnerships, EXBIO now offers a portfolio of Apronex reagents, mainly in field of allergy-screening assays and apoptosis, that are coupled with EXBIO extensive collection of Flow Cytometry kits and other reagents.
The Apronex commitment to quality and continuous improvement ensure the growth of their catalogue, mainly focusing on recombinant allergens. The acquisition of Apronex will broaden the EXBIO offering of recombinant allergens for Basophil Activation Test, but also as raw material for our industrial partners in field of allergy-screening assays.
Jolana Vosahlova, Ph.D.
EXBIO is the leading manufacturer of monoclonal antibodies and reagents for research and clinical applications with the focus on multi-color flow cytometry analysis of human cellular markers.
Our comperhensive portfolio of more than 4 000 off-the-shelf products covers a diverse set of areas including Hematology, Immunology, Cancer, Stem cells, and Cell Biology.
With the experienced cytometry experts and biotech engineers, EXBIO offers to our customers long-term validated antibody markers in the broad selection of fluorochrome conjugates.
Our commitment to the customer's needs, supported by our integrated quality management system compliant with ISO 13485:2016, ISO9001:2015 and cGMP (21 CFR part 820), allow us to accomplish our mission:
EXBIO strives to exceed the most demanding customer expectations in the field of analytical cytometry by providing a comprehensive portfolio of high quality products and services at affordable prices.
EXBIO has recently developed two new products for multicolor flow-cytometric immunophenotyping of cells of the human immune system from peripheral blood to follow up kinetics of immune responses in relation to clinical and virological features of a COVID-19 patients.
Now, we bring you a presentation of patient’s data – comparision with percentage range acquired from normal healthy donors and time-course changes in subpopulations of B and T cells of hospitalized patients diagnosed with COVID-19.